Mr. Thomas Smeenk reports
HEMOSTEMIX ANNOUNCES CLINICAL TRIAL UPDATE AND CONTRACT WITH GLOBEX DATA TO ENCRYPT ITS COMMUNICATIONS WITH REGULATORY AUTHORITIES
Hemostemix Inc. has contracted two additional clinical research associates, is completing the remaining data entry and source document verifications, and has subscribed with Globex Data Ltd. to encrypt its e-mail communications with regulatory authorities in a secure portal.
Sekur is one app that bundles encrypted e-mail, messaging and file transfer into one solution that incorporates unlimited sized attachments, data loss prevention, anti-phishing, a self-destruct timer and privacy features. Sekur e-mails between senders and recipients never leave Globex's encrypted servers based in Switzerland.
"As we near completion and reporting of the results of the HS 12-01 clinical trial, Sekur provides Hemostemix with the ultimate Switzerland-based and encrypted e-mail security that enables us to send no-size-limit attachments and comply with our regulator's secure communication standards," stated Thomas Smeenk, chief executive officer.
Alain Ghiai, chief executive officer of Globex Data, said: "With Microsoft's March announcement of its exchange on-premise business e-mail servers being breached, it is clear hackers have devised a way to reach business e-mails globally. Globex has never been connected to AWS, Microsoft Azure or Google Cloud platforms. We are a truly independent, private and secure means of communication for biotechs like Hemostemix who need to communicate with federal regulators in a secure portal."
Dec. 18, 2020, closing update
In connection with the offering that closed on Dec. 18, 2020, the company inadvertently failed to compensate two finders who assisted with the private placement for gross proceeds of $1,272,117. The corporation will pay the finders a cash finder's fee of $60,249.36 and issue finder's options entitling the finders to purchase 261,247 units of the corporation at a price of $1 within 12 months of the original closing date. Each unit comprises one common share and one purchase warrant, with each warrant entitling the holder to acquire one common share at a price of $1 within 12 months of the closing date.
About Hemostemix Inc.
Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
On Oct. 21, 2019, the company announced the results from its phase II multicentre randomized double-blind placebo-controlled clinical trial of ACP-01 in critical limb ischemia (CLI) abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup," which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years.
The company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage and Automated Cell Therapy.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.